蛋白酶活化受体-2的研究进展

蛋白酶活化受体(protease-activated receptors,PARs)属于G蛋白偶联受体家族成员,其N-末端被蛋白酶裂解后,可形成新的N-末端。新N-末端能够结合、激活自身受体。PAR-2是PARs的成员之一,其激活、灭活、脱敏、复敏、及其与信号转导途径的关系,尤其是与疾病(如呼吸道慢性炎症)的关系正倍受关注。     

蛋白酶激活受体-2在中枢神经系统的双重作用

蛋白酶激活受体-2是一种细胞膜表面受体,属于G蛋白偶联受体家族,广泛分布于全身多种组织器官,激活后参与许多疾病的发生和发展过程,尤其在中枢神经系统中所起的作用受到人们越来越多的关注。     

在食管癌细胞增殖过程中蛋白酶激活受体-2(PAR-2)对细胞周期蛋白D1(CyclinD1)的调控机制*

目的:探讨在食管癌细胞增殖过程中蛋白酶激活受体-2(PAR-2)影响细胞周期蛋白D1(CyclinD1)的机制。方法:方法:使用食管癌EC109细胞株,实验分为:空白对照组、PAR-2激动组(加入激动剂SLIGKV)、PAR-2反激动组(加入反激动剂VKGILS)、PAR-2 shRNA组(PAR-2shRNA成功转染)和MAPK抑制组(加入阻滞剂PD98059);取对数生长期的细胞,以6×10⁴cells/ml的密度接种于培养瓶中,置于孵育箱中培养24 h后使用PBS清洗3次,更换为无血清的1640培养基培养24 h,之后各实验组按实验设计分别加入所需试剂,每组设置3个复孔,于孵育箱中继续培养24 h,采用RT-PCR法检测PAR-2、ERK1、CyclinD1的mRNA的表达水平;采用Western blot法检测PAR-2、ERK1、p-ERK1、CyclinD1的蛋白表达水平。结果:与空白对照组相比,PAR-2激动组PAR-2mRNA、ERK1 mRNA、和CyclinD1 mRN表达明显升高(P＜0.05),PAR-2、p-ERK1和CyclinD1蛋白表达升高(P＜0.05);PAR-2 shRNA组PAR-2mRNA、ERK1 mRNA和CyclinD1 mRNA表达降低(P＜0.05),PAR-2、p-ERK1和CyclinD1蛋白表达降低(P＜0.05);MAPK抑制组ERK1 mRNA和CyclinD1 mRNA表达明显降低(P＜0.05),p-ERK1和CyclinD1表达降低(P＜0.05)。结论: PAR-2可通过MAPK通路调节CyclinD1的表达从而促进食管癌细胞EC109的增殖。     

蛋白酶激活受体-2在中枢神经系统的双重作用

蛋白酶激活受体-2是一种细胞膜表面受体,属于G蛋白偶联受体家族,广泛分布于全身多种组织器官,激活后参与许多疾病的发生和发展过程,咒其在中枢神经系统中所起的作用受到人们越来越多的关注.     

肥大细胞及类胰蛋白酶在人甲状腺肿瘤组织中的表达 及其与微血管密度的关系

目的:探讨肥大细胞(mast cell,MC)及类胰蛋白酶(tryptase)与甲状腺肿瘤微血管密度(microvessel density,MVD)的相关性及其对甲状腺癌发生发展的影响。方法:采用甲苯胺蓝组织化学染色和PV免疫组织化学染色对116例甲状腺癌、56例甲状腺腺瘤和10例正常甲状腺组织中MC和tryptase及其CD31的表达进行了检测;对MC和tryptase与MVD的关系进行了统计学分析。结果:甲状腺肿瘤中MC的数量和tryptase阳性表达高于正常甲状腺,而且与肿瘤的类型有关(P<0.01);Spearman等级相关分析显示各组甲状腺组织MC数量和tryptase表达与MVD呈正相关(r=0.900,r=0.636,P<0.05)。结论:MC及其分泌的tryptase有促进血管新生的作用,因而可促进甲状腺肿瘤的浸润和转移。     

柴胡皂甙(I)对胰腺腺泡的拟膜受体激动剂作用

应用检测淀粉酶分泌和单细胞[Ca^2 ]的技术,研究了Bt2-cGMP和GDP对柴胡皂甙（Ⅰ）[SA(I)]和CCK－8促大鼠胰腺腺泡分泌和增加[Ca^2 ]i的抑制作用。Bt2-cGMP对SA（I）和CCK－8促酶分泌的抑制有相似的剂量依赖性。Bt2-cGMP对SA（I）刺激的酶分泌动力学的抑制较对CCK－8滞后并持续。SA（I）诱发的胰腺腺泡单细胞[Ca^2 ]i的变化与CCK－8的作用有所不同;[Ca^2 ]i峰值上升较慢且持续较长,并在峰后[Ca^2 ]i再次升高。GDP亦抑制SA（I）刺激的酶分泌和[Ca^2 ]i增加的峰值。结果表明,SA（I）可激活胰腺腺泡细胞膜受体从而升高[Ca^2 ]i和促酶分泌。     

2种β2-受体激动剂抗血清的比较研究

目的:通过比较分析,为β2-受体激动剂的快速免疫学检测方法及最佳免疫抗血清的选择提供依据。方法:分别以偶氮化法和碳二亚胺法将β2-受体激动剂克伦特罗(CL)和沙丁胺醇(Sal)连接到牛血清白蛋白和卵清蛋白上,免疫家兔;4次免疫后,采血制备抗CL和抗Sal的抗血清;用间接ELISA检测抗血清效价,用间接抑制ELISA检测抗血清交叉反应。结果:为抗CL抗血清的效价为1∶2560,抗Sal抗血清的效价为1∶5120。抗CL抗血清对Sal有0.088%的交叉反应,而抗Sal抗血清对CL有200%的交叉反应;就对CL的抑制而言,抗Sal血清比抗CL血清更敏感。结论:在检测β2-受体激动剂CL时,Sal完全抗原可能是制备抗血清的最佳抗原。     

蛋白酶抑制剂对绿豆象幼虫中肠蛋白酶活性的影响

为明确蛋白酶抑制剂对绿豆象幼虫中肠蛋白酶活性的影响,采用室内人工接虫和生化测定的方法,研究了在离体条件和饲喂条件下4种蛋白酶抑制剂对绿豆象幼虫中肠蛋白酶的抑制作用,并测定了绿豆象幼虫取食不同含量的绿豆胰蛋白酶抑制剂(MBTI)的人工绿豆后,其中肠内总蛋白酶、类胰蛋白酶和类胰凝乳蛋白酶活性的变化.结果表明:在离体条件下,供试4种蛋白酶抑制剂对绿豆象幼虫总蛋白酶、类胰蛋白酶和类胰凝乳蛋白酶活性均有明显的抑制作用,且浓度越大,抑制效果越显著,其中以20μg·mL^-1的MBTI对3种酶活性的抑制效果最强,3种酶活性分别比对照降低了62.5%、41.2%和38.7%,而卵粘蛋白抑制剂(OI)抑制效果最弱.绿豆象幼虫取食含不同抑制剂的人工绿豆后,中肠内3种酶活性也均受到一定的抑制作用,取食后随龄期的延长,3种酶活性有所升高但仍显著低于对照,且以MBTI的抑制作用最强.当绿豆象幼虫取食不同含量MBTI的人工绿豆后,随MBTI含量的增加,对总蛋白酶活性和类胰蛋白酶活性的抑制作用均逐渐增强,但对类胰凝乳蛋白酶活性的抑制作用并不显著,只有当MBTI含量达20%时,对类胰凝乳蛋白酶活性才表现出明显的抑制作用.     

多巴胺受体拮抗剂对缢蛏多巴胺D2类受体的影响

为探究多巴胺受体拮抗剂对缢蛏多巴胺D2类受体的影响,实验以一龄缢蛏作为研究对象,以3种多巴胺受体拮抗剂多潘立酮(domperidone, Domp)、舒必利(sulpiride, Sulp)、盐酸氯丙臻(chlorprothixene hydrochloride, Chlo)为受试物,设置2 h和6 h两个时间点,探究在三种作用浓度(10~(-2)mol/L, 10~(-3)mol/L和10~(-5)mol/L)下每种受试物对缢蛏两个多巴胺D2类受体(ScDopR2-1和ScDopR2-2)表达量的抑制效果。荧光定量检测多巴胺D2类受体的表达量,并检测c AMP的含量变化。检测结果表明,10-2mol/L浓度下,Chlo组别两个多巴胺受体基因相比对照组在2 h表达量均下降,而cAMP相比对照组含量上升,因此选取Chlo作为缢蛏多巴胺D2类受体拮抗剂,浓度选为10~(-2)mol/L,本实验为进一步研究缢蛏多巴胺D2类受体的功能提供了药理学基础。     

多巴胺受体激动剂对兔动脉cAMP产生系统的影响

实验观察了选择性多巴胺（ＤＡ）ＤＡ１受体激动剂ｆｅｎｏｌｄｏｐａｍ与ＤＡ２受体激动剂ｐｒｏｐｙ１－ｂｕｔｙｌ－ｄｏｐａｍｉｎｅ（ＰＢＤＡ）对兔肾动脉,肺、肠系膜动脉和股动脉环磷酸腺苷（ｃＡＭＰ）产生系统的影响。结果表明：⑴除股动脉外,ｆｅｎｏｌｄｏｐａｍ均可浓度依赖性地增加肺动脉、肾动脉和肠系膜动脉ｃＡＭＰ的生成量。选择性ＤＡ１受体阻断剂ＳＣＨ２３３９０可以显著阻断ｆｅｎｏｌｄｏｐａｍ的效应,而Ｄ     

实电解质钙可诱发人肥大细胞组胺和类胰蛋白酶分泌

目的: 利用人大肠组织的肥大细胞和肥大细胞激活的体外研究系统,评价实电解质钙(calcium ionophore A23187, CI)诱导肥大细胞释放类胰蛋白酶和组胺的能力和机制.方法: 经酶悬浮的人大肠肥大细胞与CI共同培养后收集上清液,并用酶联免疫吸附试验(ELISA)的方法检测类胰蛋白酶分泌量,用以玻璃纤维为基础的荧光比色法检测组胺释放量.结果: 经过15 min的培养,CI可引起浓度相关性的组胺和类胰蛋白酶释放.其中组胺的最大分泌量比基础分泌量超出了5.3倍以上,而类胰蛋白酶的最大分泌量则比基础分泌量超出了2.8倍以上.CI在浓度高于1.0 μmol/L时引起的组胺释放量明显多于类胰蛋白酶释放量.时间关系曲线显示,CI的作用从加样后10 s开始,6 min后达高峰并至少持续15 min.百日咳毒素和代谢抑制剂均能抑制CI引起的组胺和类胰蛋白酶释放.结论: 人大肠肥大细胞在受到CI刺激时具有释放类胰蛋白酶和组胺的能力,这个过程与肥大细胞膜G蛋白偶联受体的激活有关,并消耗能量.     

Neovascularization and mast cells with tryptase activity increase simultaneously in human pterygium

Mast cells (MC) have been implicated in both normal and pathological angiogenesis, such as that in chronic inflammatory diseases and tumors. This assumption is partially supported by the close structural association between MC and blood vessels and the recruitment of these cells during tumor growth. MC release a number of angiogenic factors among which tryptase, a serine protease stored in MC granules, is one of the most active. In this study, we correlate the extent of angiogenesis with the number of tryptase-reactive MC in tissue fragments from pterygium and normal bulbar conjunctiva investigated by immunohistochemistry, using two murine monoclonal antibodies against the endothelial cell marker CD31 and the MC marker tryptase. Angiogenesis, measured as microvessel density, was highly correlated with MC tryptase-positive cell count in pterygium tissues. These results suggest that the characteristic neovascularization observed in pterygium may be sustained, at least in part, by MC angiogenic mediators, in particular tryptase.     

Restricted ability of human mast cell tryptase to activate proteinase-activated receptor-2 in rat aorta

We investigated the potential of human mast cell tryptase to induce relaxation of rat aorta. Trypsin and the selective PAR2-activating peptide (PAR2-AP) SLIGRL-NH2 stimulated robust relaxation of phenylephrine-precontracted rat aortic rings. However, human lung tryptase (1-100 nM) either in the presence or absence of heparin failed to induce any significant relaxation. Notwithstanding, incubation of the aorta with tryptase (100 nM), following the addition of a peptide corresponding to the cleavage/activation sequence of rat PAR2 (rPAR2), resulted in relaxation of precontracted tissue due to the proteolytic release of the PAR2-AP SLIGRL/ from the parent peptide. Thus, tryptase was enzymatically active in the bioassay system. Preincubation of aorta with neuraminidase to remove cell-surface sialic acid unmasked the ability of tryptase to induce relaxation of the aorta, but had no effect on relaxation induced by trypsin, SLIGRL-NH2, or acetylcholine (Ach). Like trypsin and SLIGRL-NH2, the tryptase-induced relaxation was inhibited by either removal of the endothelium or pretreatment of the tissue with NG-nitro-L-arginine methyl ester (L-NAME), suggesting an endothelium-derived nitric oxide mechanism. Interestingly, tryptase in the presence of heparin failed to induce relaxation of precontracted neuraminidase-treated rat aorta. We conclude that tryptase-induced relaxation of rat aorta, most likely via PAR2, is tightly regulated by heparin and cell-surface sialic acid.     

Delayed production of arachidonic acid contributes to the delay of proteinase-activated receptor-1 (PAR1)-triggered prostaglandin E2 release in rat gastric epithelial RGM1 cells

Proteinase-activated receptor-1 (PAR1), upon activation, exerts prostanoid-dependent gastroprotection, and increases prostaglandin E(2) (PGE(2)) release through cyclooxygenase-2 (COX-2) upregulation in rat gastric mucosal epithelial RGM1 cells. However, there is a big time lag between the PAR1-triggered PGE(2) release and COX-2 upregulation in RGM1 cells; that is, the former event takes 18 h to occur, while the latter rapidly develops and reaches a plateau in 6 h. The present study thus aimed at clarifying mechanisms for the delay of PGE(2) release after PAR1 activation in RGM1 cells. Although a PAR1-activating peptide, TFLLR-NH(2), alone caused PGE(2) release at 18 h, but not 6 h, TFLLR-NH(2) in combination with arachidonic acid dramatically enhanced PGE(2) release even for 1-6 h. TFLLR-NH(2) plus linoleic acid caused a similar rapid response. CP-24879, a Δ(5)/Δ(6)-desaturase inhibitor, abolished the PGE(2) release induced by TFLLR-NH(2) plus linoleic acid, but not by TFLLR-NH(2) alone. The TFLLR-NH(2)-induced PGE(2) release was not affected by inhibitors of cytosolic phospholipase A(2) (cPLA(2)), Ca(2+)-independent PLA(2) (cPLA(2)) or secretory PLA(2) (sPLA(2)), but was abolished by their mixture or a pan-PLA(2) inhibitor. Among PLA(2) isozymes, mRNA of group IIA sPLA(2) (sPLA(2)-IIA) was upregulated following PAR1 stimulation for 6-18 h, whereas protein levels of PGE synthases were unchanged. These data suggest that the delay of PGE(2) release after COX-2 upregulation triggered by PAR1 is due to the poor supply of free arachidonic acid at the early stage in RGM1 cells, and that plural isozymes of PLA(2) including sPLA(2)-IIA may complementarily contribute to the liberation of free arachidonic acid.     

Pericellular substrates of human mast cell tryptase: 72,000 dalton gelatinase and fibronectin.

Migrating cells degrade pericellular matrices and basement membranes. For these purposes cells produce a number of proteolytic enzymes. Mast cells produce two major proteinases, chymase and tryptase, whose physiological functions are poorly known. In the present study we have analyzed the ability of purified human mast cell tryptase to digest pericellular matrices of human fibroblasts. Isolated matrices of human fibroblasts and fibroblast conditioned medium were treated with tryptase, and alterations in the radiolabeled polypeptides were observed in autoradiograms of sodium dodecyl sulphate polyacrylamide gels. It was found that an M(r) 72,000 protein was digested to an M(r) 62,000 form by human mast cell tryptase while the plasminogen activator inhibitor, PAI-1, was not affected. Cleavage of the M(r) 72,000 protein could be partially inhibited by known inhibitors of tryptase but not by aprotinin, soybean trypsin inhibitor, or EDTA. Fibroblastic cells secreted the M(r) 72,000 protein into their medium and it bound to gelatin as shown by analysis of the medium by affinity chromatography over gelatin-Sepharose. The soluble form of the M(r) 72,000 protein was also susceptible to cleavage by tryptase. Analysis using gelatin containing polyacrylamide gels showed that both the intact M(r) 72,000 and the M(r) 62,000 degraded form of the protein possess gelatinolytic activity after activation by sodium dodecyl sulphate. Immunoblotting analysis of the matrices revealed the cleavage of an immunoreactive protein of M(r) 72,000 indicating that the protein is related to type IV collagenase. Further analysis of the pericellular matrices indicated that the protease sensitive extracellular matrix protein fibronectin was removed from the matrix by tryptase in a dose-dependent manner. Fibronectin was also susceptible to proteolytic degradation by tryptase. The data suggest a role for mast cell tryptase in the degradation of pericellular matrices.     

Neutrophil elastase acts as a biased agonist for proteinase-activated receptor-2 (PAR2)

Human neutrophil proteinases (elastase, proteinase-3, and cathepsin-G) are released at sites of acute inflammation. We hypothesized that these inflammation-associated proteinases can affect cell signaling by targeting proteinase-activated receptor-2 (PAR(2)). The PAR family of G protein-coupled receptors is triggered by a unique mechanism involving the proteolytic unmasking of an N-terminal self-activating tethered ligand (TL). Proteinases can either activate PAR signaling by unmasking the TL sequence or disarm the receptor for subsequent enzyme activation by cleaving downstream from the TL sequence. We found that none of neutrophil elastase, cathepsin-G, and proteinase-3 can activate G(q)-coupled PAR(2) calcium signaling; but all of these proteinases can disarm PAR(2), releasing the N-terminal TL sequence, thereby preventing G(q)-coupled PAR(2) signaling by trypsin. Interestingly, elastase (but neither cathepsin-G nor proteinase-3) causes a TL-independent PAR(2)-mediated activation of MAPK that, unlike the canonical trypsin activation, does not involve either receptor internalization or recruitment of β-arrestin. Cleavage of synthetic peptides derived from the extracellular N terminus of PAR(2), downstream of the TL sequence, demonstrated distinct proteolytic sites for all three neutrophil-derived enzymes. We conclude that in inflammation, neutrophil proteinases can modulate PAR(2) signaling by preventing/disarming the G(q)/calcium signal pathway and, via elastase, can selectively activate the p44/42 MAPK pathway. Our data illustrate a new mode of PAR regulation that involves biased PAR(2) signaling by neutrophil elastase and a disarming/silencing effect of cathepsin-G and proteinase-3.     

Localization of Protease-Activated Receptors -1 and -2 in Human Mast Cells: Indications for an Amplified Mast Cell Degranulation Cascade

Protease-activated receptors (PARs) belong to a family of G-coupled seven transmembrane receptors that are activated by a proteolytic cleavage of their N-termini. Recent studies suggest the involvement of protease-activated receptors-1 and -2 (PAR-1, PAR-2) activators in mast cell de-granulation in various physiological and pathophysiological processes in inflammatory responses. Although PAR-1 and PAR-2 activating proteases, thrombin and tryptase, have been associated with mast cell activation, PAR-1 and PAR-2 have not been localized within these cells. We describe here the localization of PAR-1 and PAR-2 in mast cells from various normal human tissues using im-munohistochemical and double immunofluorescence techniques. The presence of these receptors on the membrane may explain the actions of accessible extracellular thrombin and tryptase for mast cell activation. In addition to the membrane labeling, these receptors are also localized on the membrane of the intracellular tryptase-positive granules, which may function to sustain further mast cell degranulation upon exocytosis. The localization of these two receptors in mast cells suggests a novel mechanism for controlling mast cell activation through regulation of PARI and PAR-2.     

High density of tryptase‐positive mast cells in human colorectal cancer: a poor prognostic factor related to protease‐activated receptor 2 expression

Tryptase(+) mast cells (MCs), abundant in the invasive front of tumours, contribute to tissue remodelling. Indeed, protease‐activated receptor‐2 (PAR‐2) activation by MC‐tryptase is considered an oncogenic event in colorectal cancer (CRC). Recently, we have suggested NHERF1 as a potential new marker in CRC. In this study, we aimed to determine the distribution of tryptase(+) MCs and PAR‐2 and to examine the relationship between PAR‐2 and NHERF1, investigating their reputed usefulness as tumour markers. We studied a cohort of 115 CRC specimens including primary cancer (C) and adjacent normal mucosa (NM) by immunohistochemical double staining, analyzing the protein expression of MC‐tryptase, PAR‐2 and cytoplasmic NHERF1. MC density was higher in NM than in C. Tumours with high TNM stage and poor grade showed the highest MC density. A higher PAR‐2 immunoreactivity characterized tumours most infiltrated by MCs compared with samples with low MC density. Furthermore, PAR‐2 overexpression was associated with advanced TNM stage, poor grade and lymphovascular invasion (LVI). A positive correlation existed between tryptase(+) MC density and PAR‐2 expression. Cytoplasmic NHERF1 was higher in C than in NM and overexpressing tumours resulted associated with nodal and distant metastases, poor grade and LVI. PAR‐2 correlated with cytoplasmic NHERF1 and the PAR‐2(+)/cytoplasmic NHERF1(+) expression immunophenotype identified tumours associated with unfavourable prognosis and aggressive clinical parameters. Our data indicate that the high density of tryptase(+) MCs at invasive margins of tumours was associated with advanced stages of CRC and was strongly correlated with PAR‐2 expression.     

Agonists of proteinase-activated receptor 2 induce TNF-alpha secretion from astrocytoma cells

Proteinase-activated receptor 2 (PAR2) is cleaved and activated by trypsin or mast cell tryptase, and may play an important role in inflammation. We have investigated the potential of PAR2 agonists to modulate TNF-alpha secretion from human astrocytoma cell line CCF-STTG1. We found that CCF-STTG1 expresses PAR2 by RT-PCR and Western blot analysis. Agonists such as trypsin, the peptide SLIGKV-NH(2) (corresponding to the PAR2 tethered ligand), or mast cell tryptase directly signal to CCF-STTG1 to stimulate secretion of TNF-alpha but do not stimulate in the presence of soybean trypsin inhibitor (SBTI) or VKGILS-NH(2) (reverse peptide). The secretion of TNF-alpha by trypsin was significantly blocked by pretreatment with either 50 microM PD98059 or 1 microM SB203580. Furthermore, trypsin stimulated the activation of extracellular signal-regulated kinase (ERK) and p38 MAP kinase homologue in CCF-STTG1 without any detectable activation of c-Jun N-terminal kinase (JNK). These results show that trypsin may induce TNF-alpha secretion following activation of ERK and p38 via PAR2 in CCF-STTG1.